Bausch + Lomb (NYSE:BLCO) Stock Rating Reaffirmed by HC Wain

Bausch + Lomb (NYSE:BLCO – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They presently have a $20.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 45.56% from the company’s previous close. […]

Related Keywords

South Korea , Canada , United States , Poland , United Kingdom , France , China , Freshford , Bath And North East Somerset , Italy , Japan , Puerto Rico , Mexico , Spain , Russia , Germany , , Wells Fargo Company , Quadrature Capital Ltd , Freshford Capital Management , Royal Bank , Renaissance Capital , Gabelli Funds , Lomb Company Profile , Lomb Corporation , Barclays , Get Free Report , Lomb Stock , Funds Weigh In On Bausch , Capital Ltd , Capital Management , Allianz Asset Management Gmbh , Lomb Company , Vision Care , Lomb Daily , Bausch Lomb , Nyse Blco , Blco , Medical , Reiterated Rating , Hc Wainwright ,